These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 11350878

  • 1. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
    van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH.
    Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
    [Abstract] [Full Text] [Related]

  • 2. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, Maring JG, Vreken P, van Gennip AH.
    Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
    [Abstract] [Full Text] [Related]

  • 3. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH.
    Int J Cancer; 2002 Sep 20; 101(3):253-8. PubMed ID: 12209976
    [Abstract] [Full Text] [Related]

  • 4. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
    van Kuilenburg AB, De Abreu RA, van Gennip AH.
    Ann Clin Biochem; 2003 Jan 20; 40(Pt 1):41-5. PubMed ID: 12542909
    [Abstract] [Full Text] [Related]

  • 5. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
    Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH.
    Pharmacogenetics; 2002 Oct 20; 12(7):555-8. PubMed ID: 12360106
    [Abstract] [Full Text] [Related]

  • 6. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.
    Magy Onkol; 2007 Oct 20; 51(2):113-25. PubMed ID: 17660867
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M, Schwabe W, Häusler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Höffken K.
    Clin Cancer Res; 2001 Sep 20; 7(9):2832-9. PubMed ID: 11555601
    [Abstract] [Full Text] [Related]

  • 8. Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.
    Uzunkoy A, Dilmec F, Ozgonul A, van Kuilenburg AB, Akkafa F.
    Anticancer Res; 2007 Sep 20; 27(6B):3899-902. PubMed ID: 18225548
    [Abstract] [Full Text] [Related]

  • 9. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB.
    Eur J Cancer; 2004 May 20; 40(7):939-50. PubMed ID: 15093568
    [Abstract] [Full Text] [Related]

  • 10. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
    Ofverholm A, Arkblad E, Skrtic S, Albertsson P, Shubbar E, Enerbäck C.
    Clin Biochem; 2010 Feb 20; 43(3):331-4. PubMed ID: 19822137
    [Abstract] [Full Text] [Related]

  • 11. Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function.
    Van Kuilenburg AB, Meinsma R, Beke E, Bobba B, Boffi P, Enns GM, Witt DR, Dobritzsch D.
    Biol Chem; 2005 Apr 20; 386(4):319-24. PubMed ID: 15899693
    [Abstract] [Full Text] [Related]

  • 12. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
    Coriat R, Chaussade S.
    Therapie; 2007 Apr 20; 62(2):105-9. PubMed ID: 17582310
    [Abstract] [Full Text] [Related]

  • 13. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.
    Magné N, Etienne-Grimaldi MC, Cals L, Renée N, Formento JL, Francoual M, Milano G.
    Br J Clin Pharmacol; 2007 Aug 20; 64(2):237-40. PubMed ID: 17335544
    [Abstract] [Full Text] [Related]

  • 14. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
    Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB.
    Cancer Chemother Pharmacol; 2007 Sep 20; 60(4):503-7. PubMed ID: 17165084
    [Abstract] [Full Text] [Related]

  • 15. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
    Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB.
    Clin Cancer Res; 1999 Aug 20; 5(8):2006-11. PubMed ID: 10473079
    [Abstract] [Full Text] [Related]

  • 16. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
    Hooiveld EA, van Kuilenburg AB, Haanen JB, Westermann AM.
    Ned Tijdschr Geneeskd; 2004 Mar 27; 148(13):626-8. PubMed ID: 15083629
    [Abstract] [Full Text] [Related]

  • 17. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
    Ezzeldin H, Johnson MR, Okamoto Y, Diasio R.
    Clin Cancer Res; 2003 Aug 01; 9(8):3021-8. PubMed ID: 12912951
    [Abstract] [Full Text] [Related]

  • 18. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
    Johnson MR, Wang K, Diasio RB.
    Clin Cancer Res; 2002 Mar 01; 8(3):768-74. PubMed ID: 11895907
    [Abstract] [Full Text] [Related]

  • 19. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma.
    Morel A, Boisdron-Celle M, Fey L, Lainé-Cessac P, Gamelin E.
    Clin Biochem; 2007 Jan 01; 40(1-2):11-7. PubMed ID: 17046731
    [Abstract] [Full Text] [Related]

  • 20. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K.
    Gan To Kagaku Ryoho; 2006 Aug 01; 33(8):1041-8. PubMed ID: 16912518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.